Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
First Thing Tomorrow, Tuesday, May 12, 2025 Market Crux Launches Full Coverage on (FEED) Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.
Take A Look At (FEED) Before Tomorrow Morning…
May 11, 2026
Tomorrow’s Top Idea | See Why (Nasdaq: FEED) Just Hit Tuesday’s Watchlist
Dear Reader, At Market Crux, we look for moments when overlooked companies start showing signs that the story is changing. Right now, ENvue Medical, Inc. (NASDAQ: FEED) is flashing that kind of setup. This is not just another thinly followed medical technology name. Every year, hospitals across the United States perform more than 13M feeding tube placements — yet approximately 85% are still done blindly, without real-time visual guidance, often leaving clinicians waiting on radiology confirmation before feeding can begin. (FEED) has built a commercial-stage platform designed to address that exact problem, and over the last several days, the company has delivered a sequence of developments that deserve close attention. Most recently, (FEED) announced a three-year purchasing agreement renewal tied to one of the largest non-profit health systems in the United States, along with a fresh USPTO Notice of Allowance connected to its proprietary surface acoustic wave (SAW) technology. That combination of clinical relevance, recent headlines, and expanding commercial access is exactly why (FEED) just moved to the top of Market Crux’s watchlist heading into Tuesday morning’s session — May 12, 2026. But keep in mind, (FEED) has less than 900K shares listed as available to the public right now. When companies have small floats like this, the potential exists for big moves if demand begins to shift. In fact, earlier this year, (FEED) made an approximate 238% move in less than a week. (FEED) opened around $1.80 on January 28 and reached $3.05, for an approximate 69% move in only a few hours, according to data from Barchart. But it didn’t stop there. Two days later, on January 30, (FEED) tapped $6.09, to cap off an approximate 238% move in less than a week. 
That kind of setup is exactly why we wanted to take a closer look at what is actually behind this story. Because beyond the recent headlines and previous momentum, (FEED) has a real operating business, cleared technology, active hospital deployments, and a developing IP portfolio. So before tomorrow’s session gets underway, here is the full picture readers need to understand. Company Overview
ENvue Medical, Inc. (NASDAQ: FEED) is headquartered in Tyler, Texas, with research and development operations in Tel-Aviv and Nesher, Israel. The company operates two distinct technology platforms that together address a wide range of clinical and home-care needs. The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system that assists clinicians in placing nasoenteral feeding tubes at the bedside with real-time visual guidance. The system is FDA 510(k) cleared for adult use and is now commercially deployed across 40 U.S. hospitals, generating recurring consumable revenue as clinicians integrate it into their daily workflow. The company's second platform, the Acoustic Therapeutic Platform, includes PainShield® and UroShield® — devices utilizing proprietary low-intensity surface acoustic wave (SAW) technology designed for pain reduction, biofilm disruption, and bacterial colonization prevention in home and clinical settings. 
UroShield recently secured reimbursement approval in the UK, adding an international revenue channel through distributor Peak Medical. Leadership is anchored by Doron Besser, MD, Chief Executive Officer, with the company having named Marc Waldman as VP of Commercial in January 2026, bringing over 35 years of commercial leadership in the medical device industry. David Johnson serves as Chairman of the Board, adding deep healthcare industry governance experience. The Market Potential
(FEED) operates at the intersection of two growing sectors. The global enteral feeding devices market is valued at approximately $4.97B in 2026 and is projected to reach $8.98B by 2035, expanding at a CAGR of 6.8%. Within the U.S. alone, more than 6M patients rely on enteral feeding annually, and approximately 500,000 gastrostomy tube placements occur each year. North America commands roughly 38% of global demand, underpinned by high healthcare spending, an aging population, and rising rates of chronic disease. The clinical case for navigation-guided placement is compelling. As (FEED)’s April 2026 shareholder letter explains, pulmonary misplacement — when a tube inadvertently enters the lungs — is a preventable but potentially fatal event. Blind placement also creates imaging bottlenecks as hospitals wait on radiology confirmation before feeding can begin. Real-time bedside guidance directly addresses patient safety mandates, staffing shortages, and cost pressure — simultaneously. Commercial Momentum & Competitive Positioning
(FEED)’s hospital footprint has been growing steadily. In March 2026, the company expanded its presence within a major Michigan health system, pushing its U.S. hospital count to 39. In April 2026, ENvue announced its 40th U.S. hospital customer — a Virginia Medical Center affiliated with the Mayo Clinic Care Network. Association with the Mayo Clinic Care Network carries significant clinical credibility and signals the quality tier of institutions now adopting the platform. Most consequentially, on May 7, 2026, (FEED) announced a three-year GPO purchasing agreement renewal with one of the largest non-profit health systems in the U.S., encompassing more than 90 hospitals across 17 states, running through 2028. The strategic importance here is substantial: instead of facility-by-facility value analysis committee approvals that can take months, any participating hospital can now move directly to adoption. (FEED) CEO Doron Besser, MD, stated the arrangement makes the platform "one clinical decision away from adoption" at any participating facility. IP Portfolio Expansion & Pipeline
(FEED)’s intellectual property strategy is expanding in multiple directions. In February 2026, the USPTO issued a Notice of Allowance for a feeding tube that combines electromagnetic navigation with a distal-tip camera — enabling both positional guidance and direct internal visualization in a single device. This next-generation design has the potential to further differentiate ENvue's platform from competitors. Then on May 8, 2026, (FEED) disclosed a second USPTO Notice of Allowance for a patent covering its SAW technology applied to transdermal compound delivery. The USPTO specifically recognized a synergistic enhancement in compound absorption when combined with SAW ultrasound — a non-obvious determination that broadens (FEED)’s IP into pain management, neurology, and inflammation applications, signaling future licensing and collaboration potential. On the pipeline front, (FEED)’s stated 2026 priorities include pursuing pediatric and PICC clearances for the Navigation Platform, expanding its at-home ENFit syringe distribution nationally, and continuing to build recurring consumable revenue across its installed base. All Eyes on (FEED) Tomorrow — Here Are the 5 Reasons It's Leading Our Watchlist For Tuesday, May 12, 2026
1. Tiny Float: With less than 900K shares listed as available to the public, (FEED)’s small float could have the potential to witness big moves if demand begins to change.2. Previous Move: Earlier this year, (FEED) opened near $1.80 on January 28, reached $3.05 the same day, and tapped $6.09 two days later on January 30, marking an approximate 238% move in less than a week.3. FDA Cleared Platform: The ENvue Navigation Platform from (FEED) is FDA 510(k) cleared for adult use and commercially deployed across 40 U.S. hospitals.4. Recent Headlines: In recent days, (FEED) announced both a three-year GPO renewal and a new USPTO Notice of Allowance tied to its SAW technology.5. Expanded Reach: After reaching 40 U.S. hospitals in April 2026, (FEED) also renewed a GPO agreement tied to more than 90 hospitals across 17 states through 2028. Take A Look At (FEED) Before Tomorrow Morning…
The picture forming around (FEED) is difficult to ignore. Between a float of less than 900K shares, expanding hospital adoption, FDA-cleared technology already deployed across 40 U.S. hospitals, and a newly renewed GPO agreement tied to more than 90 hospitals through 2028, the company continues to build commercial traction while remaining largely under the radar. Add in two recent USPTO Notices of Allowance, continued platform expansion, and the kind of rapid momentum we previously witnessed earlier this year, and it becomes clear why this name has quickly returned to the top of our watchlist heading into Tuesday morning’s session. (FEED) has earned a top spot on our watchlist for tomorrow morning. Give (FEED) a good look before you call it a night Sincerely, Gary Silver
Managing Editor, Market Crux
|
Tidak ada komentar:
Posting Komentar